RAYMOND B. WEISS, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Santoro and colleagues (1) have reported a 59% complete response rate using the ABVD regimen (doxorubicin, bleomycin, vinblastine, and decarbazine) in patients with Hodgkin's disease resistant to MOPP chemotherapy (mechlorethamine, vincristine, procarbazine, and prednisone). For uncertain reasons other investigators (2-4) using approximately the same regimen and dose schedule have not achieved a similarly favorable rate of complete remission. One possible reason for this difference is that Santoro and associates state that 11 of their 54 evaluable patients had irradiation as "consolidation therapy" after receiving ABVD treatment. Either some of these 11 patients did not achieve a complete
WEISS RB. Hodgkin's Disease and the ABVD Regimen. Ann Intern Med. ;96:784. doi: 10.7326/0003-4819-96-6-784_1
Download citation file:
Published: Ann Intern Med. 1982;96(6_part_1):784.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use